share_log

华海药业:下属子公司获得药物临床试验许可

Huahai Pharmaceutical: Affiliated subsidiary obtains drug clinical trial license

Breakings ·  Mar 5, 2023 15:51
Huahai Pharmaceutical announced that its subsidiary has obtained approval for drug clinical trials. Drug name: HB0025. Indications for injection: advanced solid tumors.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment